Abstract
Recently, it was demonstrated that some anti-cancer agents used mitochondrial voltage-dependent anion channels (VDAC1–3 isoforms) as their pharmacological target. VDACs are expressed more highly in cancer cells than normal cells; thus the VDAC-dependent cytotoxic agents can have cancer-selectivity. Furanonaphthoquinones (FNQs) induced caspase-dependent apoptosis via the production of NADH-dependent reactive oxygen species (ROS) by VDAC1. The ROS production and the anti-cancer activity of FNQs were increased by VDAC1 overexpression. Meanwhile, erastin induced RAS-RAF-MEK-dependent non-apoptotic cell death via VDAC2. On the other hand, VDACs were needed for transporting ATP to hexokinase (HK), which was highly expressed in cancer cells. We hypothesized that the high glycolysis might induce up-regulation of VDAC. In this review, we propose that VDACs are novel candidates for effective pharmacological targets of anti-cancer drugs.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baker MA, Lane DJ, Ly JD, De Pinto V, Lawen A (2004) J Biol Chem 279:4811–4819
Blachly-Dyson E, Zambronicz EB, Yu WH, Adams V, McCabe ER, Adelman J, Colombini M, Forte M (1993) J Biol Chem 268:1835–1841
Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ (2003) Science 301:513–517
Colombini M (1980) Ann N Y Acad Sci 341:552–563
Earnshaw WC (1999) Nature 397:387–389
Hirai K-I, Koyama J, Pan J, Simamura E, Shimada H, Yamori T, Sato S, Tagahara K, Tsuruo T (1999) Cancer Detect Prev 23:539–550
Huizing M, Ruitenbeek W, van den Heuvel LP, Dolce V, Iacobazzi V, Smeitink JA, Palmieri F, Trijbels JM (1998) J Bioenerg Biomembr 30:277–284
Klasa RJ, Gillum AM, Klem RE, Frankel SR (2002) Antisense Nucleic Acid Drug Dev 12:193–213
Lai JC, Benimetskaya L, Khvorova A, Wu S, Hua E, Miller P, Stein CA (2005) Mol Cancer Ther 4:305–315
Lai JC, Tan W, Benimetskaya L, Miller P, Colombini M, Stein CA (2006) Proc Natl Acad Sci U S A 103:7494–7499
Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996) Cell 86:147–157
Madesh M, Hajnoczky G (2001) J Cell Biol 155:1003–1015
Mathupala SP, Ko YH, Pedersen PL (2006) Oncogene 25:4777–4786
Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y (1998) Proc Natl Acad Sci U S A 95:14681–14686
Pan J, Simamura E, Koyama J, Shimada H, Hirai KI (2000) Cancer Detect Prev 24:266–274
Pedersen PL (1978) Prog Exp Tumor Res 22:190–274
Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH (2002) Biochim Biophys Acta 1555:14–20
Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P (2006) J Cell Biol 175:913–923
Shimizu S, Narita M, Tsujimoto Y (1999) Nature 399:483–487
Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y, Tsujimoto Y (2001) J Cell Biol 152:237–250
Shinohara Y, Ishida T, Hino M, Yamazaki N, Baba Y, Terada H (2000) Eur J Biochem 267:6067–6073
Simamura E, Hirai K, Shimada H, Koyama J (2001) Tissue Cell 33:161–168
Simamura E, Hirai K, Shimada H, Pan J, Koyama J (2003) Cancer Detect Prev 27:5–13
Simamura E, Hirai K, Shimada H, Koyama J, Niwa Y, Shimizu S (2006) Cancer Biol Ther 5:1523–1529
Simamura E, Shimada H, Ishigaki Y, Hatta T, Higashi N, Hirai K-I (2008) Anat Sci Int. Available at http://www.blackwell-synergy.com/toc/asi/0/0
Tan W, Lai JC, Miller P, Stein CA, Colombini M, Loke YH, Benimetskaya L (2007a) Am J Physiol Cell Physiol 292:C1388–C1397
Tan W, Loke YH, Stein CA, Miller P, Colombini M, Lai JC, Benimetskaya L (2007b) Biophys J 93:1184–1191
Warburg O, Dickens F (1930) The metabolism of tumours: Investigations from the Kaiser-Wilhelm Institute for Biology. Berlin-Dahlem. Constable, London
Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, Smith R, Lessnick SL, Sahasrabudhe S, Stockwell BR (2007) Nature 447:864–868
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Simamura, E., Shimada, H., Hatta, T. et al. Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents. J Bioenerg Biomembr 40, 213–217 (2008). https://doi.org/10.1007/s10863-008-9158-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-008-9158-6